دورية
Betamethasone Valerate Foam for Treatment of Nonscalp Psoriasis
| العنوان: | Betamethasone Valerate Foam for Treatment of Nonscalp Psoriasis |
|---|---|
| المؤلفون: | Stein, Linda F., Sherr, Amelia, Solodkina, Galina, Gottlieb, Alice B., Chaudhari, Umesh |
| المصدر: | Journal of Cutaneous Medicine and Surgery; July 2001, Vol. 5 Issue: 4 p303-307, 5p |
| مستخلص: | Background: Although betamethasone valerate (BMV) foam, 0.12% (Luxiq™, Connectics Corporation, Palo Alto, CA) is approved by the Food and Drug Administration for the treatment of corticosteroid-responsive scalp dermatoses, no data are available for its use on nonscalp psoriasis.Objective: We evaluated the safety and efficacy of BMV foam in treating psoriatic lesions at nonscalp sites.Methods: We conducted a randomized, double-blind, placebo-controlled, paired-comparison, split-body study of 40 patients with mild to moderate plaque-type psoriasis. Patients applied BMV foam and placebo foam twice daily for 12 weeks.Results: At the end of the treatment period, 70% of patients had greater than 50% improvement of lesions on their active foam-treated side compared with 24% of patients with similar improvement on their placebo foam-treated side. Adverse effects were limited to temporary stinging, burning, or itching in several patients. Three patients (7.5%) withdrew because of stinging or itching.Conclusions: The results indicate that BMV foam is effective against nonscalp psoriasis. Twice-daily applications are well tolerated, compliance exceeds 90%, cosmetic characteristics are acceptable, and the medication may reduce the need for multiple prescriptions. |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 12034754 16157109 |
|---|---|
| DOI: | 10.1177/120347540100500404 |